Real-World Experience with Isavuconazole in Allogeneic Stem Cell Transplantation in Spain.

Autor: Kwon M; Department of Hematology, Hospital General Universitario Gregorio Marañon, Madrid, Spain; Department of Hematology, Instituto de Investigación Sanitaria Gregorio Marañon, Madrid, Spain. Electronic address: mi.kwon@salud.madrid.org., Gómez-Centurión I; Department of Hematology, Hospital General Universitario Gregorio Marañon, Madrid, Spain; Department of Hematology, Instituto de Investigación Sanitaria Gregorio Marañon, Madrid, Spain., Oarbeascoa G; Department of Hematology, Hospital General Universitario Gregorio Marañon, Madrid, Spain; Department of Hematology, Instituto de Investigación Sanitaria Gregorio Marañon, Madrid, Spain., Torres M; Department of Hematology, Hospital Universitario de Gran Canaria Dr. Negrin, Las Palmas de Gran Canaria, Spain., Martinez AP; Department of Hematology, Hospital Clínico Universitario de Valencia, Valencia, Spain., Suarez-Lledó M; Department of Hematology, Hospital Clinic Institute of Hematology & Oncology, Barcelona, Spain., Chinea A; Department of Hematology, Hospital Universitario Ramon y Cajal, Madrid, Spain., Cascón MJP; Department of Hematology, Hospital Regional de Málaga, Málaga, Spain., Vazquez L; Department of Hematology, Hospital Universitario de Salamanca, Salamanca, Spain., Espigado I; Department of Hematology, Department of Medicine, University of Seville, HUV Macarena-HUV Rocío, IBiS/CSIC, Sevilla, Spain., Izquierdo I; Department of Hematology, Hospital Universitario Miguel Servet, Zaragoza, Spain., Parody R; Department of Hematology, Institut Català Oncologia-Hospital Duran i Reynals, Barcelona, Spain., Cadenas IG; Department of Hematology, Hospital de La Santa Creu I Sant Pau, Barcelona, Spain., Calbacho M; Department of Hematology, Hospital Universitario 12 de Octubre, Madrid, Spain., Sierra PG; Department of Hematology, Hospital Universitario Virgen de las Nieves, Granada, Spain., Heras I; Department of Hematology, Hospital Universitario Morales Meseguer, Murcia, Spain., Yañez L; Department of Hematology, Hospital Universitario Marqués de Valdecilla, Santander, Spain., Torrent A; Department of Hematology, Institut Català d'oncologia, Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain., Bautista G; Department of Hematology, Hospital Universitario Puerta de Hierro, Majadahonda, Madrid, Spain., Gonzalez S; Department of Hematology, Hospital Universitario Central de Asturias, Oviedo, Spain., Roldan E; Department of Hematology, Vall d'Hebron Instituto de Oncología, Barcelona, Spain., Vallejo JC; Department of Hematology, Hospital Universitario Donostia, Donostia, Spain., Bailen R; Department of Hematology, Hospital General Universitario Gregorio Marañon, Madrid, Spain; Department of Hematology, Instituto de Investigación Sanitaria Gregorio Marañon, Madrid, Spain., Borrero A; Department of Hematology, Hospital Universitario de Gran Canaria Dr. Negrin, Las Palmas de Gran Canaria, Spain., Lopez-Jiménez J; Department of Hematology, Hospital Universitario Ramon y Cajal, Madrid, Spain., Casas MAC; Department of Hematology, Hospital Regional de Málaga, Málaga, Spain., Solano C; Department of Hematology, Hospital Clínico Universitario de Valencia, Valencia, Spain.
Jazyk: angličtina
Zdroj: Transplantation and cellular therapy [Transplant Cell Ther] 2024 Oct; Vol. 30 (10), pp. 1033.e1-1033.e8. Date of Electronic Publication: 2024 Jun 12.
DOI: 10.1016/j.jtct.2024.06.009
Abstrakt: Invasive fungal infections (IFI) pose a significant complication after hematopoietic stem cell transplantation (HSCT). Isavuconazole (ISV) is a new generation azole with a favourable adverse effect and interaction profile approved for the treatment of invasive aspergillosis and mucormycosis. We analyzed the indications, effectiveness, adverse event profile and drug interaction management of ISV in the real-world setting in adults who received allogeneic-HSCT (allo-HSCT) within the Spanish Group of HSCT and Cell Therapy (GETH-TC). We conducted a multicenter retrospective study of all consecutive adult allo-HSCT recipients (≥18 years) who received ISV either for IFI treatment or prophylaxis, from December 2017 to August 2021, in 20 centers within the Spanish Group of Hematopoietic Stem Cell Transplantation and Cell Therapy (GETH-TC). A total of 166 adult allografted patients who received ISV from 2017 to 2021 were included. Median age was 48 years with 43% females. In 81 (49%) patients, ISV was used for treatment of IFI, and in 85 (51%) for prophylaxis. Median duration of ISV administration for IFI treatment was 57 days (range 31-126) and 86 days (range 33-196) for prophylaxis. Most frequent indication for treatment was invasive aspergillosis (78%), followed by mucormycosis (6%). Therapeutic success (45%) was the most frequent reason for ISV withdrawal. In the prophylaxis group, the resolution of IFI risk factors was the most frequent reason for withdrawal (62%). Six (7%) breakthrough IFI were reported. The majority of patients (80%) presented pharmacologic interactions. Twenty-one patients (13%) reported adverse events related to ISV, mainly liver biochemistry abnormalities, which led to ISV withdrawal in 7 patients (4%). ISV was effective and well tolerated for IFI treatment and prophylaxis, with a manageable interaction profile.
(Copyright © 2024 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: